Cargando…
COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus
Since the very beginning of the COVID-19 pandemic, different treatment strategies have been explored. These mainly involve the development of antimicrobial, antiviral, and/or anti-inflammatory agents as well as vaccine production. However, other potential options should be more avidly investigated s...
Autores principales: | da Costa, Camila B.P., Martins, Francislene J., da Cunha, Luis E.R., Ratcliffe, Norman A., Cisne de Paula, Rafael, Castro, Helena C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678452/ https://www.ncbi.nlm.nih.gov/pubmed/33302034 http://dx.doi.org/10.1016/j.intimp.2020.107220 |
Ejemplares similares
-
RHEUMATOID FACTOR PROPERTIES OF HYPERIMMUNE RABBIT SERA
por: Christian, Charles L.
Publicado: (1963) -
Development of an ELISA for distinguishing convalescent sera with Mycoplasma hyopneumoniae infection from hyperimmune sera responses to bacterin vaccination in pigs
por: Ding, Honglei, et al.
Publicado: (2021) -
The Use of Hyperimmune Chicken Reference Sera Is Not Appropriate for the Validation of Influenza Pseudotype Neutralization Assays
por: Ferrara, Francesca, et al.
Publicado: (2017) -
Immune Maturation Effects on Viral Neutralization and Avidity of Hyperimmunized Equine Anti-SARS-CoV-2 Sera
por: González Viacava, Myriam Belén, et al.
Publicado: (2022) -
Development of an indirect ELISA for detecting humoral immunodominant proteins of Mycoplasma hyopneumoniae which can discriminate between inactivated bacterin-induced hyperimmune sera and convalescent sera
por: Ding, Honglei, et al.
Publicado: (2019)